MAP4K4 and cancer: A priori, the mechanistic basis for selective protection of cardiomyocytes but not tumor cells, strictly dichotomous across the seven human cell lines tested thus far, might relate to (i) DOX killing cardiomyocytes versus cancer cells in distinguishable ways, MAP4K4 inhibitors engaging preferentially the former, or (ii) DOX killing cardiomyocytes and cancer cells in identical ways, but with differing susceptibility to MAP4K4 inhibitors—in short, differences in the dying versus differences in the rescue, contingent on cell type.